Mass screening for hepatitis B and C in South Upper Egypt: lessons learned from a real life experience

2018 ◽  
Vol 68 ◽  
pp. S180-S181
Author(s):  
G. Soliman ◽  
M. Elzalabany ◽  
T. Hassanein ◽  
D. Miller
Keyword(s):  
Hepatitis B ◽  
Mass Screening ◽  
Life Experience ◽  
Real Life ◽  
Lessons Learned ◽  
Upper Egypt

scholarly journals Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir

2015 ◽  
Vol 9 (2) ◽  
pp. 57-62
Author(s):  
Rosanna Villani ◽  
Roberta Forlano ◽  
Gianluigi Vendemiale ◽  
Gaetano Serviddio
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Hepatitis B ◽  
Serum Creatinine ◽  
Viral Replication ◽  
Creatinine Clearance ◽  
Chronic Hepatitis B ◽  
Life Experience ◽  
Real Life ◽  
High Serum

INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy.PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and blood urea), serum (calcium and phosphate blood level) and urine electrolyte were also studied.RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended.CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.

scholarly journals Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience

2019 ◽  
Vol 25 (1) ◽  
pp. 12-16
Author(s):  
Abdulrahman A. Aljumah ◽  
Nawaf A. Bin Selayem ◽  
Sultan Y. Al-Howti ◽  
Mutasim Dafallah ◽  
Hamdan AlGhamdi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Life Experience ◽  
Real Life ◽  
Virological Outcomes

Sa1309 Real-Life Experience in Chronic Hepatitis B Treatment With Tenofovir and Entecavir

2014 ◽  
Vol 146 (5) ◽  
pp. S-259
Author(s):  
Helder Cardoso ◽  
Filipe Vilas-Boas ◽  
Rosa Coelho ◽  
Susana Rodrigues ◽  
Ana Horta e Vale ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Life Experience ◽  
Real Life ◽  
Hepatitis B Treatment

scholarly journals Holding a Conference Online and Live due to Covid-19

2021 ◽  
Vol 49 (4) ◽  
pp. 28-32
Author(s):  
Angela Bonifati ◽  
Giovanna Guerrini ◽  
Carsten Lutz ◽  
Wim Martens ◽  
Lara Mazilu ◽  
...  
Keyword(s):  
Life Experience ◽  
Real Life ◽  
Research Community ◽  
Lessons Learned ◽  
Face To Face ◽  
International Conference ◽  
Database Theory ◽  
The Face ◽  
Database Technology ◽  
Online Experience

The joint EDBT/ICDT conference (International Conference on Extending Database Technology / International Conference on Database Theory) is a well established conference series on data management, with annual meetings in the second half of March that attract 250 to 300 delegates. Three weeks before EDBT/ICDT 2020 was planned to take place in Copenhagen, the rapidly developing Covid-19 pandemic led to the decision to cancel the face-to-face event. In the interest of the research community, it was decided to move the conference online while trying to preserve as much of the real-life experience as possible. As far as we know, we are one of the first conferences that moved to a fully synchronous online experience due to the COVID- 19 outbreak. By fully synchronous, we mean that participants jointly listened to presentations, had live Q&A, and attended other live events associated with the conference. In this report, we share our decisions, experiences, and lessons learned.

Sign in / Sign up

Export Citation Format

Share Document